Evidence map›Paper›PMID 39113040›Full record

ReviewCancer cell international2024

Harnessing exosomes as cancer biomarkers in clinical oncology.

Subhrojyoti Ghosh, Ramya Lakshmi Rajendran, Atharva A Mahajan, Ankita Chowdhury, Aishi Bera, Sudeepta Guha, Kashmira Chakraborty, Rajanyaa Chowdhury, Aritra Paul, Shreya Jha and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Liquid biopsy in modern medicine: advancing diagnostics from molecular insights to clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Subhrojyoti Ghosh *Department of Biotechnology, Indian Institute of Technology, Madras, Chennai, 600036, India.
Ramya Lakshmi Rajendran *Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea.
Atharva A Mahajan *Advance Centre for Treatment, Research and Education in Cancer (ACTREC), Navi Mumbai, 410210, India.
Ankita ChowdhuryDepartment of Biochemical Engineering and Biotechnology, Indian Institute of Technology, Delhi, Delhi, 110016, India.
Aishi BeraDepartment of Biotechnology, Heritage Institute of Technology, Kolkata, 700107, India.
Sudeepta GuhaDepartment of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines), Dhanbad, Jharkhand, 826004, India.
Kashmira ChakrabortyDepartment of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines), Dhanbad, Jharkhand, 826004, India.
Rajanyaa ChowdhuryDepartment of Biotechnology, Heritage Institute of Technology, Kolkata, 700107, India.
Aritra PaulDepartment of Biotechnology, Heritage Institute of Technology, Kolkata, 700107, India.
Shreya JhaDepartment of Biomedical Engineering, National Institute of Technology, Rourkela, Orissa, 769008, India.
Anuvab DeyDepartment of Biosciences and Bioengineering, Indian Institute of Technology, Guwahati, Assam, 781039, India.
Amit DubeyComputational Chemistry and Drug Discovery Division, Quanta Calculus, Greater Noida, Uttar Pradesh, India.
Sukhamoy GoraiDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Purbasha DasDepartment of Life Sciences, Presidency University, Kolkata, West Bengal, 700073, India.
Chae Moon HongDepartment of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea.
Anand KrishnanDepartment of Chemical Pathology, Office of the Dean, School of Pathology, Faculty of Health Sciences, University of the Free State, Bloemfontein, 9300, Free State, South Africa. krishnana1@ufs.ac.za.
Prakash GangadaranDepartment of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea. prakashg@knu.ac.kr.
Byeong-Cheol AhnDepartment of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea. abc2000@knu.ac.kr.

Funding

National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) NRF-2022R1A2C2005057
6 · The paper itself

Abstract

Exosomes are extracellular vesicles well known for facilitating cell-to-cell communication by distributing essential macromolecules like proteins, DNA, mRNA, lipids, and miRNA. These vesicles are abundant in fluids distributed throughout the body, including urine, blood, saliva, and even bile. They are important diagnostic tools for breast, lung, gastrointestinal cancers, etc. However, their application as cancer biomarkers has not yet been implemented in most parts of the world. In this review, we discuss how OMICs profiling of exosomes can be practiced by substituting traditional imaging or biopsy methods for cancer detection. Previous methods like extensive imaging and biopsy used for screening were expensive, mostly invasive, and could not easily provide early detection for various types of cancer. Exosomal biomarkers can be utilized for routine screening by simply collecting body fluids from the individual. We anticipate that the use of exosomes will be brought to light by the success of clinical trials investigating their potential to enhance cancer detection and treatment in the upcoming years.

Indexed as

Cancer biomarkersCancer diagnosisClinical signatureDiagnostic toolExosomesMolecular profilingPrognostic indicatorTumor-derived exosomes

Identifiers

PMID39113040
PMCPMC11308730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.